Exploring the plasmatic platelet-activating factor acetylhydrolase activity in patients with anti-phospholipid antibodies

ConclusionsPAF-AH plasmatic activity is particularly up-regulated in LAC+ and in a β2GPI IgG+ patients, possibly representing an alternative prognostic biomarker for the therapeutic management of APS patients.
Source: Autoimmunity Highlights - Category: Allergy & Immunology Source Type: research